51:04

IDEF Educational Series Experience EBGLYSS lebrikizumab lbkz A New Treatment Option

58:07

Real-Time PCR in Action

4:26

Tarlatamab: Mechanism of Action and Clinical Success in Small Cell Lung Cancer │ Pharmacology

1:01:18

Staphylococcus: Aureus, Epidermidis, Saprophyticus

4:50

Sofpironium: Say Goodbye to Sweaty Underarms (Hyperhidrosis)│ Pharmacology: Mechanism of Action

1:01:30

Webinar: Community Update with ITF Therapeutics: Introducing DUVYZAT™ (givinostat) [March 2024]

41:47

MACSQuant® Tyto® Cell Sorter:Validating a fluorescence sorter for infectious diseases [WEBINAR]

6:38

Results of phase III trial of lebrikizumab in moderate-to-severe AD at 52 weeks, A. Blauvelt et al.